• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Rupal S. Bhatt, MD, PhD


  • Bhatt RS, Atkins MB.Molecular Pathways: Can Activin-Like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?.Clin Cancer Res. 2014 Apr 8.
  • Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS.The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma.Transl Oncol. 2014 Mar 4.
  • Beddy P, Genega EM, Ngo L, Hindman N, Wei J, Bullock A, Bhatt RS, Atkins MB, Pedrosa I.Tumor necrosis on magnetic resonance imaging correlates with aggressive histology and disease progression in clear cell renal cell carcinoma.Clin Genitourin Cancer. 2014 Feb;12(1):55-62.
  • Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS.Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.Br J Cancer. 2013 Feb 5;108(2):319-26.
  • Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW.Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling.Mol Cancer Ther. 2010 Oct;9(10):2793-802.
  • Bhatt RS, Zhang L, Bullock A, Moreno K, Signoretti S, Atkins M, Sabbadini R, Mier J.Sphingosine-1-phosphate (S1P) as a novel target in renal cancer (RCC).AACR Proceedings 2010..
  • Bullock AJ, Zhang L, AM O’Neill, Percy A, Sukhatme V, Mier JW, Atkins MB, Bhatt RS.Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC).J Clin Oncology AACR Proceedings 2010.;28(15s).
  • Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP.A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.Cancer. 2010 Apr 1;116(7):1751-6.
  • Bhatt R, Wang X, Zhang L, Bhasin M, Libermann T, O’Neil A, Signoretti S, Atkins M, Mier J, Goldberg SN.Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models.AACR Proceedings 2009..
  • Cho DC,Puzanov I,Regan MM,Schwarzberg T,Seery V,Lee MY,Liu V,Bhatt R,Koon H,Mier JW,Sosman JA,Atkins MB,McDermott DF.Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma.J Immunother. 2009 Feb-Mar;32(2):181-5.
  • Bhatt RS,Bubley GJ.The challenge of herbal therapies for prostate cancer.Clin Cancer Res. 2008 Dec 1;14(23):7581-2. Review.
  • Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ.Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.BJU Int. 2008 Aug;102(3):358-63.
  • Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott DF, Atkins MB, Sukhatme VP.Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.Clin Cancer Res. 2007 Apr 1;13(7):2115-20.
  • Bhatt RS, Seth P, Sukhatme VP.Biomarkers for monitoring antiangiogenic therapy.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):777s-780s. Review.